Honest Assessment
Not national security theater. Not "China is winning." The actual concern: US biotech R&D capacity could hollow out the way manufacturing did. Here's an honest look at the problem and whether this policy solves it.
This is what happened to manufacturing, semiconductors, shipbuilding, solar panels. The US invented these industries, then lost the capacity to do them.
Innovation happens here
Labor, regulation, overhead
Cheaper to do elsewhere
Scientists, infrastructure go
Can't rebuild even if we want
It's not that China "wins" and America "loses" some race. It's that the US could lose the capacity to do biotech R&D even if it wanted to. Once the scientists leave, the infrastructure closes, and the institutional knowledge disperses, you can't just rebuild it. Ask the semiconductor industry.
Not everything framed as a "China threat" is actually threatening. Here's an honest breakdown.
80%+ of antibiotics, analgesics from China. During conflict or pandemic, they could restrict exports. We saw supply anxiety during COVID. This is real.
If all Phase 2/3 trials migrate to China, US loses trial infrastructure, CRO capacity, and trained workforce. Development jobs are most at risk.
BGI and PLA-linked companies collecting American genetic data is concerning. But this is specific companies doing specific surveillance work—not the whole Chinese biotech industry. BIOSECURE already targets this.
If more R&D happens in China, fewer US jobs. Legitimate economic concern. But it's protectionism, not national security. Be honest about what it is.
If China invents a better cancer drug, that's good for American cancer patients. Science isn't zero-sum. Chinese innovation coming to US market is a feature, not a bug.
This is backwards. Licensing deals are China's IP coming to us. US workers run trials, manufacturing, sales. The IP theft concern is real elsewhere, but licensing is the opposite dynamic.
Some advantages are real comparative advantage. Some are self-inflicted US wounds.
| China Advantage | Can US Match It? | Should US Match It? |
|---|---|---|
| Lower labor costs | No | Not without destroying living standards |
| Larger patient population | No | Can't manufacture 1B more Americans |
| Faster regulatory approval | Yes | FDA reform is possible and overdue |
| Government subsidies | Yes | Could do CHIPS-style biotech investment |
| Centralized health data | Partially | Privacy tradeoffs Americans may not accept |
| Different ethical standards | No | Shouldn't compromise patient protections |
Some of China's advantage is just comparative advantage (labor costs, population). But some is the US shooting itself in the foot:
Honest answer: partially. It's an indirect solution to a problem that has more direct fixes.
If the goal is "preserve US biotech R&D capacity," here's how different policies rank:
| Policy | Impact | Feasibility | Notes |
|---|---|---|---|
| FDA reform | High | Low | Biggest lever, hardest politically |
| CHIPS-for-biotech | High | Medium | Direct manufacturing subsidy |
| Immigration reform | High | Low | Keep scientists who train here |
| NIH expansion | Medium | Medium | Requires appropriations |
| CHINA PAYS | Medium | High | Indirect but politically easy |
| R&D tax credits | Medium | High | Already exists, could expand |
CHINA PAYS tries to have it both ways. Here's the uncomfortable tradeoff.
Then taxing it reduces the incentive to bring innovative drugs to US patients. We're making it more expensive to access innovation that helps Americans. The $41B in licensing deals exists because those drugs help people.
Then a 15% tax is a half-measure. If it's truly dangerous, ban it (like BIOSECURE does for specific bad actors). You can't simultaneously argue "existential threat" and "let's skim 15%."
CHINA PAYS is best understood as industrial policy, not national security policy.
The real argument: "We want to maintain US biotech capacity, and taxing Chinese biotech to fund US biotech is a politically feasible way to do that." That's a legitimate position. It's just not the same as "China is an existential biotech threat."
The hollowing out concern is real. CHINA PAYS addresses it indirectly by generating revenue for US biotech investment. But the money could be spent poorly (government R&D funding is hit-or-miss), and you're taxing something that currently helps US patients.
Here's a detailed breakdown of policy alternatives, ranked by impact, with order-of-magnitude estimates for each. The goal is "preserve US biotech R&D capacity."
Why it ranks lower than direct policies: CHINA PAYS generates revenue that could fund US biotech, but it's an indirect mechanism. The money has to be appropriated wisely (government isn't great at this). And you're taxing innovation that helps US patients to maybe fund innovation that might help them later.
Why it might actually happen: "China pays for American biotech" is an incredible political message. Doesn't require appropriations. Doesn't require immigration reform. Doesn't require FDA to change. It's the art of the possible in a dysfunctional political system.
| Policy | Cost | Value Created | ROI | Feasibility |
|---|---|---|---|---|
| FDA Reform | ~$0 | $50-100B+ | ∞ | Very Low |
| CHIPS-for-Biotech | $20-50B | $200B+ | 4-7x | Medium |
| Immigration | ~$200M | $30-50B+ | 150-250x | Very Low |
| NIH Expansion | $10-20B/yr | $30-60B/yr | 2-3x | Medium |
| Tax Credits | $3-5B/yr | $5-10B/yr | 1.5-2x | High |
| CHINA PAYS | $0 | $5-6B/yr | ∞ | High |
I ranked by potential impact on the actual problem (US biotech capacity), not by political feasibility. If you ranked by feasibility, CHINA PAYS and tax credits would be #1-2, and the actually effective policies would be at the bottom.
This is the core tragedy: the policies that would most effectively preserve US biotech capacity are politically hardest. CHINA PAYS is a politically viable workaround that generates some money for the problem, but doesn't address why the problem exists. It's treating the symptom (capital shortage) while ignoring the disease (regulatory burden, talent outflow, cost disadvantage).
US biotech R&D capacity could hollow out like manufacturing did. Development and manufacturing jobs are migrating. This is legitimate.
An indirect solution that generates revenue for US biotech. Better than nothing, not as good as direct reforms. Politically easy, substantively medium.
FDA reform, immigration reform, direct subsidies. Higher impact but harder politically. CHINA PAYS might be the art of the possible.
We built this site to make the strongest case for CHINA PAYS. But intellectual honesty requires acknowledging: it's a B+ policy for a problem that has A+ solutions we lack the political will to implement.